ELV INVESTOR NOTICE: Elevance Health, Inc. Investors with Losses are Notified of the Ongoing Securities Fraud Class Action and July 11 Deadline – BFA Law (NYSE:ELV)

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to misleading statements about Medicaid cost trends and financial guidance [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid and Elevance - Elevance provides health insurance plans, including Medicaid benefits, which were subject to a review pause during COVID-19 that ended in 2023 [3]. - The company claimed to be monitoring cost trends related to the Medicaid redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Allegations and Financial Impact - Allegations state that the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].